Oct 15 (Reuters) - MeiraGTx Holdings PLC :
* MEIRAGTX HOLDINGS: POSITIVE DATA FROM RANDOMIZED, SHAM-CONTROLLED CLINICAL BRIDGING STUDY OF AAV-GAD FOR TREATMENT OF PARKINSON'S DISEASE
* MEIRAGTX HOLDINGS PLC: PRIMARY STUDY OBJECTIVE OF SAFETY AND TOLERABILITY WAS MET
* MEIRAGTX HOLDINGS: SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE DEMONSTRATED FOR KEY EFFICACY ENDPOINTS AT 26 WEEKS
* MEIRAGTX HOLDINGS: AAV-GAD WAS SAFE & WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS RELATED TO AAV-GAD TREATMENT
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。